Briefly, anti-PD-1 therapy induces CD8+ T cell infiltration in melanoma tumors and tumor cell-intrinsic oxidative activity, while non-glycolytic tumor metabolism hinders anti-PD-1 efficacy. This evidence concerns the gene PDCD1 and neoplasm.